{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981468928467712.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1056/nejmoa040431"}},{"identifier":{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa040431"}},{"identifier":{"@type":"NAID","@value":"30022560710"}}],"dc:title":[{"@value":"Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981468928467716","@type":"Researcher","foaf:name":[{"@value":"Patrick Marcellin"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467714","@type":"Researcher","foaf:name":[{"@value":"George K.K. Lau"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467720","@type":"Researcher","foaf:name":[{"@value":"Ferruccio Bonino"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467724","@type":"Researcher","foaf:name":[{"@value":"Patrizia Farci"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467725","@type":"Researcher","foaf:name":[{"@value":"Stephanos Hadziyannis"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467717","@type":"Researcher","foaf:name":[{"@value":"Rui Jin"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467721","@type":"Researcher","foaf:name":[{"@value":"Zhi-Meng Lu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467719","@type":"Researcher","foaf:name":[{"@value":"Teerha Piratvisuth"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467723","@type":"Researcher","foaf:name":[{"@value":"Georgios Germanidis"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467713","@type":"Researcher","foaf:name":[{"@value":"Cihan Yurdaydin"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467722","@type":"Researcher","foaf:name":[{"@value":"Moises Diago"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467712","@type":"Researcher","foaf:name":[{"@value":"Selim Gurel"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467718","@type":"Researcher","foaf:name":[{"@value":"Ming-Yang Lai"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467726","@type":"Researcher","foaf:name":[{"@value":"Peter Button"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981468928467715","@type":"Researcher","foaf:name":[{"@value":"Nigel Pluck"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00284793"},{"@type":"EISSN","@value":"15334406"}],"prism:publicationName":[{"@value":"New England Journal of Medicine"}],"dc:publisher":[{"@value":"Massachusetts Medical Society"}],"prism:publicationDate":"2004-09-16","prism:volume":"351","prism:number":"12","prism:startingPage":"1206","prism:endingPage":"1217"},"reviewed":"false","url":[{"@id":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa040431"}],"createdAt":"2004-09-15","modifiedAt":"2021-06-25","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004232067135360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142740438272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Restoration of type I interferon signaling in intrahepatically primed CD8+ T cells promotes functional differentiation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360022305560636288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Understanding hepatitis B virus dynamics and the antiviral effect of interferon-α treatment in humanized chimeric mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714664842368","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714965416192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617824940288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214486272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214789888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182504089088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185916732416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232188278784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Possible biological mechanisms of entecavir <i>versus</i> tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232420830080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643463251456","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861707377081472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814738709120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795197696","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of chronic hepatitis B which achieved hepatitis B surface antigen seroclearance during combination therapy with peginterferon alfa-2b and entecavir"},{"@language":"ja","@value":"エンテカビル・ペグインターフェロンα－２ｂ併用４８週治療にてＨＢｓ抗原が消失したＢ型慢性肝炎の１例"},{"@value":"症例報告 エンテカビル・ペグインターフェロンα-2b併用48週治療にてHBs抗原が消失したB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク エンテカビル ・ ペグインターフェロンa-2b ヘイヨウ 48シュウ チリョウ ニテ HBs コウゲン ガ ショウシツ シタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001288124282368","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"核酸アナログ4剤抵抗性でインターフェロン投与が奏効したB型肝硬変の1例"},{"@language":"en","@value":"A case of liver cirrhosis with multidrug-resistant hepatitis B virus that responded to interferon therapy"},{"@value":"症例報告 核酸アナログ4剤抵抗性でインターフェロン投与が奏効したB型肝硬変の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク カクサン アナログ 4ザイ テイコウセイ デ インターフェロン トウヨ ガ ソウコウ シタ Bガタ カンコウヘン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771702272","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and safety of treatment with peginterferon alfa-2a for chronic hepatitis B patients"},{"@language":"ja","@value":"B型慢性肝炎患者に対するペグインターフェロンα-2aの有効性及び安全性の検討"},{"@language":"ja-Kana","@value":"Bガタ マンセイ カンエン カンジャ ニ タイスル ペグインターフェロンa-2a ノ ユウコウセイ オヨビ アンゼンセイ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681377615360","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型肝炎の治療-遺伝子型と治療について-"},{"@language":"en","@value":"Therapy for chronic hepatitis B: relationship between HBV genotype and efficacy or resistance of anti-viral therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681378046208","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型慢性肝炎への抗ウイルス療法の現状と問題点"},{"@language":"en","@value":"Evidence based antiviral therapy for chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681420403968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"3. Future of Anti-viral Agents"},{"@language":"ja","@value":"3．抗ウイルス薬の将来"},{"@value":"抗ウイルス薬の将来"},{"@language":"ja-Kana","@value":"コウウイルスヤク ノ ショウライ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390852945233580416","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"International cooperation on health and medical care for viral hepatitis: 30 years of activities on comprehensive viral hepatitis control of the JICA group training program for developing countries"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750285604864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of research and management of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225550106880","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572700526864512","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Management of HBV infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550386807424","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Improving outcomes for patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975317212928","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Appropriate use of interferon for treatment of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975837321088","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmoa040431"},{"@type":"CIA","@value":"30022560710"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.42_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1016/j.cmi.2016.12.014_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1172/jci.insight.145761_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1101/2020.07.28.224840_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.4254/wjh.v7.i23.2427_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.135_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.35772/ghm.2021.01068_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1007/s00535-020-01707-6_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.2957/kanzo.60.63_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1128/jvi.00492-20_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1189-x_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1360-z_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1128/aac.00183-17_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.2169/naika.97.50_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1111/jgh.16178_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.3390/v14112468_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1136/gutjnl-2016-312653_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1016/j.virol.2018.08.020_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1111/hepr.13768_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.1007/s00535-023-02070-y_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"},{"@type":"CROSSREF","@value":"10.3892/br.2017.944_references_DOI_H1J8lzooJgsD0nDRhpryClEgabh"}]}